Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes

2005 ◽  
Vol 41 (11) ◽  
pp. 1628-1636 ◽  
Author(s):  
Wen G. Jiang ◽  
Julian Sampson ◽  
Tracey A. Martin ◽  
Lisa Lee-Jones ◽  
Gareth Watkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Promoter Methylation ◽  
Human Breast Cancer ◽  
Human Breast

scholarly journals Is oestrogen receptor- β a predictor of endocrine therapy responsiveness in human breast cancer?

2006 ◽  
Vol 13 (2) ◽  
pp. 327-334 ◽  
Author(s):  
Leigh C Murphy ◽  
Peter H Watson
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Endocrine Therapy ◽  
Prospective Studies ◽  
Human Breast Cancer ◽  
Oestrogen Receptor ◽  
The Other ◽  
Human Breast ◽  
Er Status

The role of oestrogen receptor (ER) β in human breast cancer remains unclear. However, it is now apparent that when considering ER β in human breast cancer it is important to recognise two ER β expressing groups, one in which ER β is co-expressed with ER α and the other where ERβ is expressed alone. Emerging data support different functions between ER β when it is expressed alone and when it is co-expressed with ER α. With regard to the latter group (ER α +/ER β +), there are now 9 out of 10 retrospective clinical outcome studies published, that support the hypothesis that increased expression of ER β is associated with increased likelihood of response to endocrine therapy. The data strongly support undertaking prospective studies to determine if the addition of ERβ to ER α is clinically beneficial and whether to include both ER β and ER α when establishing clinically relevant cut-offs for defining ER status.

Sign in / Sign up

Export Citation Format

Share Document